Antibodies binding to vista at acidic pH
The present application relates to antibodies specifically binding to the V-domain immunoglobulin-containing suppressor of T-cell activation (VISTA) at acidic pH and their use in cancer treatment. In some embodiments, the antibodies bind specifically to human VISTA at acidic pH, but do not significantly bind to human VISTA at neutral or physiological pH.
1. An isolated antibody that binds specifically to human VISTA (hVISTA), wherein the antibody comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH and VL comprise the complementarity determining regions (CDRs) of P1-070976 (SEQ ID Nos: 509-511 and 500-502, respectively), P1-070976_H95D (SEQ ID Nos: 512-514 and 500-502, respectively), VISTA.4 (SEQ ID Nos: 503-505 and 500-502, respectively), P1-065333 (SEQ ID Nos: 506-508 and 500-502, respectively), or P1-070976_E97P (SEQ ID Nos: 515-517 and 500-502, respectively).
2. The isolated antibody of claim 1 , wherein the VH comprises an amino acid sequence that is at least 90% identical to the VH of P1-070976 (SEQ ID NO: 474), P1-070976_H95D (SEQ ID NO: 477), VISTA.4 (SEQ ID NO: 492), P1-065333 (SEQ ID NO: 473), or P1-070976_E97P (SEQ ID NO: 478); and/or
wherein the VL comprises an amino acid sequence that is at least 90% identical to the VL of P1-070976, P1-070976_H95D, VISTA.4, P1-065333, or P1-070976_E97P (corresponding to SEQ ID NO: 493 or SEQ ID NO: 479).
3. The isolated antibody of claim 1 , wherein the VH comprises an amino acid sequence that is at least 95% identical to the VH of P1-070976 (SEQ ID NO: 474), P1-070976_H95D (SEQ ID NO: 477), VISTA.4 (SEQ ID NO: 492), P1-065333 (SEQ ID NO: 473), or P1-070976_E97P (SEQ ID NO: 478); and/or
wherein the VL comprises an amino acid sequence that is at least 95% identical to the VL of P1-070976, P1-070976_H95D, VISTA.4, P1-065333, or P1-070976_E97P (corresponding to SEQ ID NO: 493 or SEQ ID NO: 479).
4. The isolated antibody of claim 1 , wherein the antibody comprises the VH of P1-070976 (SEQ ID NO: 474), P1-070976_H95D (SEQ ID NO: 477), VISTA.4 (SEQ ID NO: 492), P1-065333 (SEQ ID NO: 473), or P1-070976_E97P (SEQ ID NO: 478); and/or wherein the antibody comprises the VL of P1-070976, P1-070976_H95D, VISTA.4, P1-065333, or P1-070976_E97P (corresponding to SEQ ID NO: 493 or SEQ ID NO: 479).
5. The isolated antibody of claim 1 , wherein the antibody comprises a heavy chain (HC) that is at least 90% identical to the HC of P1-070976.IgG1.3 (SEQ ID NO: 476), P1-070976_H95D.IgG1.3 (SEQ ID NO: 480), VISTA.4.IgG1.3 (SEQ ID NO: 491), P1-06533.IgG1.3 (SEQ ID NO: 475), or P1-070976_E97P.IgG1.3 (SEQ ID NO: 481); and/or wherein the antibody comprises a light chain (LC) that is at least 90% identical to the LC of P1-070976.IgG1.3, P1-070976_H95D.IgG1.3, VISTA.4.IgG1.3, P1-06533.IgG1.3, or P1-070976_E97P.IgG1.3, either with or without a A64G substitution in the VL (SEQ ID No: 482 or 494).
6. The isolated antibody of claim 1 , wherein the antibody comprises a heavy chain (HC) that is at least 95% identical to the HC of P1-070976.IgG1.3 (SEQ ID NO: 476), P1-070976_H95D.IgG1.3 (SEQ ID NO: 480), VISTA.4.IgG1.3 (SEQ ID NO: 491), P1-06533.IgG1.3 (SEQ ID NO: 475), or P1-070976_E97P.IgG1.3 (SEQ ID NO: 481); and/or wherein the antibody comprises a light chain (LC) that is at least 95% identical to the LC of P1-070976.IgG1.3, P1-070976_H95D.IgG1.3, VISTA.4.IgG1.3, P1-06533.IgG1.3, or P1-070976_E97P.IgG1.3, either with or without a A64G substitution in the VL (SEQ ID No: 482 or 494).
7. The isolated antibody of any claim 1 , wherein the antibody comprises the HC of P1-070976.IgG1.3 (SEQ ID NO: 476), P1-070976_H95D.IgG1.3 (SEQ ID NO: 480), VISTA.4.IgG1.3 (SEQ ID NO: 491), P1-06533.IgG1.3 (SEQ ID NO: 475), or P1-070976_E97P.IgG1.3 (SEQ ID NO: 481); and/or
wherein the antibody comprises the LC of P1-070976.IgG1.3, P1-070976_H95D.IgG1.3, VISTA.4.IgG1.3, P1-06533.IgG1.3, or P1-070976_E97P.IgG1.3, either with or without a A64G substitution in the VL (SEQ ID No: 482 or 494).
8. The isolated antibody of claim 1 , comprising a heavy chain constant region comprising IgG1.3 (SEQ ID NO: 163), a wildtype IgG1 (SEQ ID NO: 182), a wildtype IgG2, a wildtype IgG3, a wildtype IgG4, a wildtype IgG4 comprising S228P, IgG1.1 (SEQ ID NO: 183), IgG1.P238K (SEQ ID NO: 184), with or without a C-terminal lysine.
9. The isolated antibody of claim 1 , comprising a HC comprising SEQ ID NO: 476, 480, 475, 491, or 481.
10. The isolated antibody of claim 1 , comprising a light chain comprising SEQ ID NO: 482, 472, or 494.
11. The isolated antibody of claim 1 , comprising a HC and a LC, comprising the amino acid sequences of:
(a) SEQ ID NO: 476 and SEQ ID NO: 482 or 472, respectively;
(b) SEQ ID NO: 476 and SEQ ID NO: 494, respectively;
(c) SEQ ID NO: 480 and SEQ ID NO: 482 or 472, respectively;
(d) SEQ ID NO: 480 and SEQ ID NO: 494, respectively;
(e) SEQ ID NO: 475 and SEQ ID NO: 482 or 472, respectively;
(f) SEQ ID NO: 475 and SEQ ID NO: 494, respectively;
(g) SEQ ID NO: 491 and SEQ ID NO: 482 or 472, respectively;
(h) SEQ ID NO: 491 and SEQ ID NO: 494, respectively;
(i) SEQ ID NO: 481 and SEQ ID NO: 482 or 472, respectively; or
(j) SEQ ID NO: 481 and SEQ ID NO: 494, respectively.
12. The isolated antibody of claim 1 , wherein the isolated antibody binds specifically to hVISTA in acidic conditions, and wherein acidic conditions are conditions having a pH of 6.0 to 6.5.
13. The isolated antibody of claim 1 , wherein the isolated antibody has one or more of the following properties:
(a) binds specifically to hVISTA in acidic conditions, but not significantly in neutral or physiological conditions;
(b) binds to hVISTA in acidic conditions with a K D that is at least 10 fold lower than its K D in neutral or physiological conditions;
(c) binds to hVISTA in acidic conditions with a k off that is at least 5 fold, at least 10 fold, at least 50 fold, or at least 100 fold lower than its k off in neutral or physiological conditions;
(d) inhibits the binding of hVISTA to human T cells in conditions having a pH of less than pH 7.0;
wherein acidic conditions are conditions having a pH of 6.0 to 6.5, wherein neutral conditions are conditions having a pH of 7.0, and wherein physiological conditions are conditions having a pH of 7.4.
14. The isolated antibody of claim 1 , wherein the antibody inhibits VISTA mediated T cell activation as measured by NF-kB inhibition using Jurkat NF-kB-luciferase reporter cells.
15. An isolated nucleic acid or a set of at least two isolated nucleic acids encoding the antibody of claim 1 .
16. A cell comprising the isolated nucleic acid of claim 15 .
17. A method of preparing an antibody, comprising culturing the cell of claim 16 in conditions under which the antibody is expressed.
18. A composition comprising the isolated antibody of claim 1 and a pharmaceutically acceptable carrier.
19. A method of treating cancer in a subject, comprising administering to the subject a therapeutically effective amount of the antibody of claim 1 .
20. A method of treating an infectious disease in a subject, comprising administering to the subject a therapeutically effective amount of the antibody of claim 1 .